Background The value of guided therapy (GT) with anti-P2Y12 drugs in percutaneous
coronary intervention (PCI) is unclear. Meta-analyses lumped together randomized …

The role of antiplatelet therapy in patients with acute coronary syndromes is a moving target
with considerable novelty in the last few years. The pathophysiological basis of the treatment …

Potent P2Y 12 receptor antagonists have been used widely for patients undergoing
percutaneous coronary intervention with different results. Benefits from different regimens …

Rationale Antiplatelet therapy (APT) is the standard of care after endovascular
revascularization (EVR) in patients with peripheral artery disease (PAD). APT aims to …

Coronary artery disease (CAD) often leads to adverse events resulting in significant disease
burdens. Underlying risk factors often remain inapparent prior to disease incidence and the …

Stent thrombosis (ST) is a fatal complication after percutaneous coronary intervention (PCI).
The association between P2Y12 reaction unit (PRU) level and stent thrombosis occurrence …

Abstract Purpose of Review Identification of a reliable discriminatory test to accurately stratify
patient responses to antiplatelet therapy following coronary revascularization has become …

Portal vein tumor thrombosis (PVTT), a severe complication of hepatocellular carcinoma
(HCC), markedly influences patient prognosis by fostering a hypercoagulable state …

Clopidogrel is the most widely used P2Y12 receptor inhibitor (P2Y12i) as a part of dual
antiplatelet therapy along with aspirin. Clopidogrel is a pro-drug and is metabolized to its …

The use of dual anti-platelet therapy (DAPT), the combination of aspirin+ a loading dose of a
P2Y12 inhibitor, is standard of care in patients with ST-elevation myocardial infarction …